Aaron Tward, MD, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Aaron Tward, MD, PhD

Assistant Professor in Residence, Dept. of Otolaryngology, UCSF

Aaron.Tward@ucsf.edu

Phone: (415) 353-2757
Box 0342, UCSF
San Francisco, CA 94143

UCSF Profiles

Cancer Center Membership

Associate Member » Cancer Genetics

Research Summary

Aaron D. Tward M.D., Ph.D., is a board-certified, fellowship-trained surgeon who specializes in the diagnosis and treatment of disorders of the ear and skull base.

Dr. Tward has particular clinical interests in cochlear implantation, management of benign and malignant tumors of the skull base including acoustic neuroma (vestibular schwannoma), surgery for chronic otitis media, stapedectomy, superior semi-circular canal dehiscence repair, and endoscopic surgery of the ear and skull base.

Dr. Tward’s research interests include tumor biology, the genetics and genomics of disorders of the head and neck, and clinical outcomes of surgery of the ear and skull base.

Education

UCLA, B.S., 06/99, Microbiology and Molecular Genetics
UCLA, M.A., 06/99, Microbiology and Molecular Genetics
UCSF School of Medicine, Ph.D., 06/05, Biomedical Sciences
UCSF School of Medicine, M.D., 06/07, Medicine Brigham and Women's Hospital
Harvard Medical School Internship, 06/08, General Surgery


Professional Experience

  • 2012
    Harvard Otolaryngology Residency Program, Harvard Medical School, Resident, Otolaryngology - Head and Neck Surgery
  • 2014
    Massachusetts Eye and Ear Infirmary, Harvard Medical School, Fellow, Neurotology - Skull Base Surgery
  • 2014-present
    Assistant Professor in Residence, Dept. of Otolaryngology, UCSF

Selected Publications

  1. Camarda R, Zhou AY, Kohnz RA, Balakrishnan S, Mahieu C, Anderton B, Eyob H, Kajimura S, Tward A, Krings G, Nomura DK, Goga A. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat Med. 2016 Apr; 22(4):427-32.
    View on PubMed
  2. Puram SV, Tward AD, Jung DH, Dilger AE, Herrmann BS, Duhaime AC, Barker FG, Lee DJ. Auditory brainstem implantation in a 16-month-old boy with cochlear hypoplasia. Otol Neurotol. 2015 Apr; 36(4):618-24.
    View on PubMed
  3. Li J, Chanrion M, Sawey E, Wang T, Chow E, Tward A, Su Y, Xue W, Lucito R, Zender L, Lowe SW, Bishop JM, Powers S. Reciprocal interaction of Wnt and RXR-a pathways in hepatocyte development and hepatocellular carcinoma. PLoS One. 2015; 10(3):e0118480.
    View on PubMed
  4. Mroz EA, Tward AD, Tward AM, Hammon RJ, Ren Y, Rocco JW. Intra-tumor genetic heterogeneity and mortality in head and neck cancer: analysis of data from the Cancer Genome Atlas. PLoS Med. 2015 Feb; 12(2):e1001786.
    View on PubMed
  5. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015 Jan 29; 517(7536):576-82.
    View on PubMed
  6. Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, Lee S, Hadjipanayis AG, Ivanova EV, Wilkerson MD, Protopopov A, Yang L, Seth S, Song X, Tang J, Ren X, Zhang J, Pantazi A, Santoso N, Xu AW, Mahadeshwar H, Wheeler DA, Haddad RI, Jung J, Ojesina AI, Issaeva N, Yarbrough WG, Hayes DN, Grandis JR, El-Naggar AK, Meyerson M, Park PJ, Chin L, Seidman JG, Hammerman PS, Kucherlapati R. Characterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci U S A. 2014 Oct 28; 111(43):15544-9.
    View on PubMed
  7. Mroz EA, Tward AD, Pickering CR, Myers JN, Ferris RL, Rocco JW. High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Cancer. 2013 Aug 15; 119(16):3034-42.
    View on PubMed
  8. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortés ML, Auclair D, Berger MF, Saksena G, Guiducci C, Onofrio RC, Parkin M, Romkes M, Weissfeld JL, Seethala RR, Wang L, Rangel-Escareño C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Winckler W, Ardlie K, Gabriel SB, Meyerson M, Lander ES, Getz G, Golub TR, Garraway LA, Grandis JR. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011 Aug 26; 333(6046):1157-60.
    View on PubMed
  9. Lee SA, Ho C, Roy R, Kosinski C, Patil MA, Tward AD, Fridlyand J, Chen X. Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer. Hepatology. 2008 Apr; 47(4):1200-10.
    View on PubMed
  10. Tward AD, Jones KD, Yant S, Cheung ST, Fan ST, Chen X, Kay MA, Wang R, Bishop JM. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci U S A. 2007 Sep 11; 104(37):14771-6.
    View on PubMed
  11. Goga A, Yang D, Tward AD, Morgan DO, Bishop JM. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med. 2007 Jul; 13(7):820-7.
    View on PubMed
  12. Sneddon JB, Zhen HH, Montgomery K, van de Rijn M, Tward AD, West R, Gladstone H, Chang HY, Morganroth GS, Oro AE, Brown PO. Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc Natl Acad Sci U S A. 2006 Oct 3; 103(40):14842-7.
    View on PubMed
  13. Bhasin KK, Yu JM, Tward A, Shih D, Campbell DA, Lusis AJ. Trypanosoma congolense: paraoxonase 1 prolongs survival of infected mice. Exp Parasitol. 2006 Nov; 114(3):240-5.
    View on PubMed
  14. Sheth SS, Bodnar JS, Ghazalpour A, Thipphavong CK, Tsutsumi S, Tward AD, Demant P, Kodama T, Aburatani H, Lusis AJ. Hepatocellular carcinoma in Txnip-deficient mice. Oncogene. 2006 Jun 15; 25(25):3528-36.
    View on PubMed
  15. Furlong CE, Cole TB, Jarvik GP, Pettan-Brewer C, Geiss GK, Richter RJ, Shih DM, Tward AD, Lusis AJ, Costa LG. Role of paraoxonase (PON1) status in pesticide sensitivity: genetic and temporal determinants. Neurotoxicology. 2005 Aug; 26(4):651-9.
    View on PubMed
  16. Cole TB, Walter BJ, Shih DM, Tward AD, Lusis AJ, Timchalk C, Richter RJ, Costa LG, Furlong CE. Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism. Pharmacogenet Genomics. 2005 Aug; 15(8):589-98.
    View on PubMed
  17. Furlong CE, Cole TB, Walter BJ, Shih DM, Tward A, Lusis AJ, Timchalk C, Richter RJ, Costa LG. Paraoxonase 1 (PON1) status and risk of insecticide exposure. J Biochem Mol Toxicol. 2005; 19(3):182-3.
    View on PubMed
  18. Tward AD, Jones KD, Yant S, Kay MA, Wang R, Bishop JM. Genomic progression in mouse models for liver tumors. Cold Spring Harb Symp Quant Biol. 2005; 70:217-24.
    View on PubMed
  19. Araujo JA, Meng L, Tward AD, Hancock WW, Zhai Y, Lee A, Ishikawa K, Iyer S, Buelow R, Busuttil RW, Shih DM, Lusis AJ, Kupiec-Weglinski JW. Systemic rather than local heme oxygenase-1 overexpression improves cardiac allograft outcomes in a new transgenic mouse. J Immunol. 2003 Aug 1; 171(3):1572-80.
    View on PubMed
  20. Cole TB, Jampsa RL, Walter BJ, Arndt TL, Richter RJ, Shih DM, Tward A, Lusis AJ, Jack RM, Costa LG, Furlong CE. Expression of human paraoxonase (PON1) during development. Pharmacogenetics. 2003 Jun; 13(6):357-64.
    View on PubMed

Go to UCSF Profiles, powered by CTSI